Blurbs

Analysts Are Bullish on Top Healthcare Stocks: Assembly Biosciences (ASMB), X4 Pharmaceuticals (XFOR)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Assembly Biosciences (ASMBResearch Report) and X4 Pharmaceuticals (XFORResearch Report) with bullish sentiments.

Assembly Biosciences (ASMB)

Mizuho Securities analyst Salim Syed maintained a Buy rating on Assembly Biosciences yesterday and set a price target of $14.00. The company’s shares closed last Wednesday at $2.17.

According to TipRanks.com, Syed is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -16.5% and a 35.4% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Coherus Biosciences, and Unity Biotechnology.

Currently, the analyst consensus on Assembly Biosciences is a Moderate Buy with an average price target of $9.50.

See today’s best-performing stocks on TipRanks >>

X4 Pharmaceuticals (XFOR)

In a report released yesterday, Leah R. Cann from Brookline Capital Markets maintained a Buy rating on X4 Pharmaceuticals, with a price target of $6.50. The company’s shares closed last Wednesday at $1.14, close to its 52-week low of $0.86.

According to TipRanks.com, Cann is a 3-star analyst with an average return of 1.2% and a 44.6% success rate. Cann covers the Healthcare sector, focusing on stocks such as Crispr Therapeutics AG, Intellia Therapeutics, and Syros Pharmaceuticals.

X4 Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $7.80.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ASMB:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos